INS and diabetes mellitus: The studies with sulfonylurea, metformin, insulin, and the thiazolidinediones provide support for the recommendation that improvement of glycemic control has long term benefits on ASCVD risk in both type 1 and 2 diabetes although they did not point to a clear target for this treatment.